Type 1 diabetes mellitus (DM) induces systemic endothelial dysfunction, even before clinical microvascular or macrovascular angiopathies become manifest ([@B1]--[@B5]). It is characterized by increased vascular permeability and elevated plasma levels of endothelium-derived proteins like von Willebrand factor (vWF) ([@B2],[@B3]). Endothelial dysfunction is related to increased glycemia, the most important risk factor for clinical diabetic angiopathies ([@B3]--[@B5]), but its pathogenesis is unclear.

Vascular endothelial growth factor (VEGF)-A is a potent angiogenic cytokine, released by hypoxic cells, activated platelets, leukocytes, and cancer cells ([@B6]--[@B13]). It increases vascular permeability in vivo and activates endothelial cells in vitro, leading to protein kinase C activation and release of several proteins for which plasma levels are elevated in vivo due to diabetic endothelial dysfunction ([@B6],[@B14]). In cultured endothelial cells, VEGF production is induced by high levels of glucose and advanced glycation end products ([@B15]--[@B18]). Taken together, VEGF may play an important role in the pathogenesis of endothelial dysfunction ([@B14],[@B16],[@B18]). In support of this notion, VEGF plasma levels were found to be higher in diabetic persons than in control subjects ([@B19]--[@B22]), and a correlation of plasma VEGF levels with both diabetic nephropathy (DN) and proliferative retinopathy has been reported ([@B23]--[@B25]).

As VEGF is released by activated platelets ([@B7]--[@B10]), as occurs in serum samples, platelet activation during blood collection could be an artificial source of VEGF in plasma samples as well, but this possibility was not explored in the studies mentioned ([@B19],[@B23],[@B24]). VEGF levels in plasma samples may correlate with blood platelet activation at the time of blood sampling rather than represent the steady-state plasma levels of VEGF in vivo. This may explain conflicting results in studies of VEGF plasma levels in DM and other conditions with endothelial dysfunction ([@B14],[@B20]--[@B22],[@B26]--[@B29]).

Artificial ex vivo platelet activation during blood collection procedures can be largely inhibited by using anticoagulants to which a mixture of prostaglandin E~1~ and theophylline has been added (e.g., PECT medium) ([@B30]). When combined with measurements for platelet factor 4 (PF4), a marker for ex vivo artificial platelet activation in blood samples ([@B31]), and β-thromboglobulin (β-TG), a marker for in vivo platelet activation ([@B31]), PECT plasma allows a more accurate estimation of the actual levels of VEGF circulating in vivo. Using this approach, we have shown in a recent study that VEGF levels in the circulation of patients with metastasized cancer are very low, in contrast to many previous reports that were based on VEGF levels in citrate or EDTA plasma analyses ([@B32]).

In the current study, we compared VEGF measurements in blood samples of diabetic persons and control subjects collected in citrate and PECT medium. We investigated: *1*) whether VEGF levels found in citrate plasma levels were different from those found in PECT plasma; and *2*) whether VEGF levels in citrate and PECT plasma correlate with parameters of diabetes and endothelial dysfunction such as HbA~1c~ levels, glucose levels, vWF levels, or with the presence of diabetic retinopathy (DR) and DN.

RESEARCH DESIGN AND METHODS {#s1}
===========================

Subjects {#s2}
--------

Twenty-one healthy subjects (category 1) and 64 consecutive patients with type 1 DM, without DR and DN (category 2; *n* = 21), with DR but without DN (category 3; *n* = 25), or with both DR and DN (category 4; *n* = 18) participated in the study. Retinopathy was defined according to the definitions of the Early Treatment Diabetic Retinopathy Study Research Group ([@B33]); DN was defined as such when albuminuria \>30 mg/24 h, when not explained by other causes than DM. The study was approved by the Medical Ethical Committee of our institute, and patients gave their written informed consent ([@B34]).

After an overnight fast and abstaining from vigorous physical activity during the previous 24 h, patients presented at the outpatient clinic between 8:00 and 10:00 [a.m.]{.smallcaps}, bringing their 24-h urine collection for measurement of urinary creatinine and albumin excretion. Demographic and relevant medical history data were recorded: age, sex, diabetes duration, insulin dose, comorbidity, medication, and smoking habits ([Table 1](#T1){ref-type="table"}). Blood pressure was measured with a sphygmomanometer in the sitting position: the median of three successive measurements was noted. Height and weight were measured. The degree of DR was scored by an experienced ophthalmologist (R.O.S.) by fundoscopic examination and examination of the clinical charts as no DR (A), nonproliferative DR (B), preproliferative DR (C), or proliferative DR (D), and previous panretinal photocoagulation therapy was noted. Demographic and clinical data are given in [Table 1](#T1){ref-type="table"} according to the division in categories.

###### 

Demographic and clinical parameters according to category
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Anticoagulants {#s3}
--------------

From each patient or volunteer, venous blood was taken with a microperfuser (diameter 1 mm; Microflex; Vycon, Ecouen, France) and divided into different tubes. Plastic (polypropylene) blood-collection tubes were filled with 400 µL of a solution containing: prostaglandin E~1~ (94 nmol/L), Na~2~CO~3~ (0.63 mmol/L), EDTA (90 mmol/L), and theophyllin (10 mmol/L) (PECT medium). Blood samples (4 mL) were collected in these PECT tubes in an open system, drop by drop, without using a tourniquet to (maximally) avoid platelet activation ex vivo. Blood was also collected in tubes filled with citrate (BD Vacutainers Systems, Breda, the Netherlands). Blood collected in the PECT and citrate tubes was immediately placed on ice. Platelet-depleted PECT plasma was prepared by spinning for 60 min at 1,700*g* at 4°C within 1 h after collection. The citrate blood samples were centrifuged within 30 min for 15 min at 1,000*g* to obtain plasma.

Measurements of metabolic markers {#s4}
---------------------------------

Plasma creatinine levels were measured using an automated spectrophotometrical assay using creatininase, glucose with automated spectrophotometrical assay using glucose dehydrogenase, and glycated HbA~1c~ with high-performance liquid chromatography. In 24-h urine samples, creatinine was measured by the Jaffé method, albumin with an immunonephelometric assay, and renal creatinine clearance was calculated.

Measurements of markers of platelet activation and endothelial dysfunction and VEGF {#s5}
-----------------------------------------------------------------------------------

Platelet count was determined by automated optical scatter detection. Levels of vWF antigen (antibodies from DakoCytomation, Glostrup, Denmark), β-TG (Asserachrom β-TG; Diagnostica Stago, Roche, Almere, the Netherlands), PF4 (Asserachrom PF 4; Diagnostica Stago), and VEGF (R&D Systems, Abingdon, U.K.) were determined by ELISA.

Statistical analysis {#s6}
--------------------

Statistical analysis was performed with the computer program SPSS version 12.0 (SPSS, Gorinchem, the Netherlands). Values are given as mean (± SD). Differences between subject categories were analyzed by ANOVA. Comparison of means for variables between non-DM and DM patient groups were performed with the Student *t* test for unpaired data. Pearson correlation coefficients were calculated between VEGF plasma levels and clinical indicators of microvascular complications, markers of glycemia, and platelet activation. Forward multiple linear regression analysis was performed with VEGF plasma levels as the dependent variable and those determinants that correlated in the univariate analysis with *P* \< 0.10 as independent variables. With multiple comparisons, the level of significance was set at *P* \< 0.01.

RESULTS {#s7}
=======

[Table 1](#T1){ref-type="table"} shows that microvascular complications were related to duration of DM and age. Systolic blood pressure and use of ACE inhibitors per category increased with microvascular complications. Glycemic control and fasting glucose levels increased with DM categories ([Table 2](#T2){ref-type="table"}), and creatinine clearance, increasing albuminuria, and increased vWF plasma levels were related with DM and endothelial dysfunction ([Table 2](#T2){ref-type="table"}).
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VEGF levels in blood samples {#s8}
----------------------------

In PECT plasma, VEGF levels were invariably low in both non-DM and DM subjects \[mean ± SD (range): 6.1 ± 9.4 (0--35) vs. 6.1 ± 9.5 (0--45) pg/mL\]. VEGF levels in PECT plasma did not correlate with any markers of DM, endothelial dysfunction, in vivo or ex vivo platelet activation, DR, and DN.

In contrast, VEGF levels in citrate plasma were significantly higher in DM patients as compared with control subjects \[16.5 ± 12.0 (1--63) vs. 10.4 ± 4.9 (3--20) pg/mL; *P* = 0.03; [Fig. 1](#F1){ref-type="fig"}\] and correlated positively with HbA~1c~ levels (*r* = 0.40; *P* \< 0.0001), fasting glucose levels (*r* = 0.31; *P* \< 0.004), vWF levels (*r* = 0.35; *P* \< 0.002), PF4 levels (*r* = 0.32; *P* \< 0.005), DR grade (*r* = 0.29; *P* \< 0.007), and previous retinal photocoagulation (*r* = 0.34; *P* \< 0.003) ([Fig. 2](#F2){ref-type="fig"}). VEGF levels in citrate plasma showed no relation with VEGF levels in PECT plasma of the same patients, in vivo platelet activation, platelet count, smoking, blood pressure, or albuminuria.

![Distribution of VEGF levels in citrate plasma (VEGF~CITRATE~; mean indicated by horizontal lines) in healthy subjects (*N* = 21) and patients with type 1 DM (*N* = 64).](1629fig1){#F1}

![The relationship between VEGF levels in citrate plasma (VEGF~CITRATE~) and its putative determinants in healthy subjects and patients with type 1 DM: glycated HbA~1c~ (*A*), PF4 (*B*), vWF (*C*), fasting glucose (*D*), and previous treatment with panretinal laser photocoagulation (*E*).](1629fig2){#F2}

Multiple linear regression analysis indicated that only PF4 and HbA~1c~ levels were independent predictors of VEGF levels in citrate plasma (regression equation of citrate plasma levels was VEGF = −7.58 + 1.9 HbA~1c~ + 0.08 PF4; *r* = 0.47; *P* = 0.0002). The residual sum of the squares indicated that 22% of the variation in VEGF levels in citrate plasma was explained by HbA~1c~ and PF4 levels in citrate plasma. This indicates that VEGF in citrate plasma samples is derived from ex vivo platelet activation, but also that in patients with poor glycemic control, more VEGF is released ex vivo.

Platelet activation in vivo and in blood samples ex vivo {#s9}
--------------------------------------------------------

To further explore the cause of elevated VEGF in citrate plasma samples in type 1 DM, we investigated the contribution of in vivo platelet activation to VEGF levels in plasma. β-TG levels, as a measure of in vivo platelet activation (measured in case subjects without any ex vivo platelet activation as indicated by PF4 level \<10 IU), were similar in DM subjects compared with non-DM subjects, indicating that platelet activation in vivo is not altered in type 1 DM.

In citrate plasma samples, PF4 was used as parameter for ex vivo platelet activation. PF4 levels were not higher in DM subjects as compared with non-DM subjects ([Table 2](#T2){ref-type="table"}), indicating that platelets of DM and non-DM subjects are activated to a similar extent by blood-collection procedures. Taken together, our findings indicate that the higher levels of VEGF in citrate plasma samples in type 1 diabetes are caused by higher release of VEGF by individual platelets upon activation by the blood-harvesting procedure, in particular in patients with poorer glycemic control.

Although not correlated with type 1 DM per se, β-TG levels in PECT plasma correlated positively with albuminuria (*r* = 0.38; *P* = 0.005), indicating that DN is associated with increased platelet activation in vivo.

CONCLUSIONS {#s10}
===========

The most important finding reported in this article is that free VEGF is only present at low levels in the circulation, both in DM and non-DM subjects, when platelet activation is inhibited during blood-sampling procedures by the use of PECT. This argues against a role of circulating VEGF in endothelial dysfunction in type 1 DM. Previous studies have suggested such a role on the basis of VEGF levels found in citrate or EDTA plasma ([@B19],[@B23],[@B24]). We demonstrate in this study that the two- to threefold higher VEGF levels in citrate plasma compared with PECT plasma, as were reported in the literature ([@B19],[@B23],[@B24]) and confirmed in the current study, originate from artificial ex vivo release of VEGF in plasma samples. The main sources of VEGF in blood are activated platelets and leukocytes ([@B10],[@B11]), whereas in PECT medium, platelet activation but not leukocyte activation is inhibited ([@B30]). Therefore, our results suggest that activated platelets are the main source of VEGF in citrate plasma samples. The strong correlation between citrate plasma levels of VEGF and PF4, a marker for ex vivo platelet activation ([@B31]), confirms this conclusion.

These observations are in line with results from our recent study ([@B32]) in cancer patients in whom levels of circulating VEGF, reported by others as a biomarker for angiogenic activity ([@B35]), were studied in PECT plasma compared with citrate or EDTA plasma ([@B32]). This study indicated that levels of freely circulating VEGF are not elevated in the majority of cancer patients with widespread metastases. Only patients with renal cell carcinoma, a cancer type characterized by excessive VEGF production due to a specific genetic defect, showed elevated circulating VEGF levels. In addition, this study indicated that the elevated plasma VEGF levels in cancer patients previously reported by others can be explained by release from platelets with an increased VEGF content, activated during the blood-harvest procedure ([@B32],[@B36]).

As in cancer patients, levels of VEGF in citrate plasma samples were significantly higher in patients with type 1 DM than in non-DM subjects. In multivariate analysis, only HbA~1c~ and PF4 were found to be independent determinants of VEGF levels in citrate plasma. As platelet activation in vivo was not increased in our DM subjects as compared with non-DM subjects, the correlation of VEGF levels with PF4 indicates that ex vivo release of VEGF from platelets activated during blood sample collection is an important source of VEGF in citrate plasma samples. The independent correlation between VEGF and HbA~1c~, which has not been reported previously, suggests that in type 1 diabetes, poor glycemic control alters individual platelets in such a way that more VEGF is released upon activation. This is in line with our study in cancer, which showed that elevated levels of VEGF in citrate plasma samples could be explained by an increased VEGF content of individual platelets in patients with metastatic cancer ([@B36]). We can only speculate what these results mean for the understanding of a possible role of VEGF in endothelial dysfunction in type 1 DM ([@B4],[@B5]), but the possibility of higher release of VEGF from individual platelets in tissue capillaries in patients with poor glycemic control should be explored as a potential contributor to endothelial dysfunction in diabetic patients ([@B37]).

However, the low levels of VEGF in PECT plasma indicate that efficient mechanisms exist in the circulation to remove or inactivate this potent cytokine ([@B38]). One of these may be elevated levels of the soluble VEGF receptor sFLT-1 in DM ([@B21]), but platelets may also have a role in this respect. In fact, studies of VEGF in blood in cancer patients not only suggest that platelets are a carrier of VEGF, but also that platelets may act as scavengers of free VEGF in the circulation ([@B8]--[@B10],[@B36]). Another explanation of our results is therefore that individual platelets in type 1 DM carry more VEGF that has been scavenged after being produced in tissues, possibly induced by high plasma levels of glucose and/or advanced glycation end products ([@B15]--[@B18],[@B39]). This explanation is supported by our finding and that of others that in patients with proliferative DR, in whom high amounts of VEGF are produced in the eye ([@B6]), particularly high VEGF levels were found in citrate plasma ([@B25]) but not in PECT plasma and by our observation that increased in vivo platelet activation in patients with established DN was not associated with an increase in VEGF levels in PECT plasma.

In conclusion, *1*) the low levels of VEGF in vivo as determined in PECT plasma do not support a role of circulating VEGF in endothelial dysfunction in type 1 DM; *2*) platelet activation in PECT plasma (ex vivo) or in vivo is not increased in DM in general, but platelet activation in vivo is associated with DN; *3*) VEGF in citrate plasma mainly originates from artificial ex vivo release by activated platelets, and the higher levels previously reported in DM appear due to increased release of VEGF by platelets related to poor glycemic control; and *4*) VEGF plasma levels have to be measured while avoiding ex vivo platelet activation.
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